GlassScriptPhysician profile
Keith K Woo
NPI 1366595092
$105,854.99
in general payments reported to CMS, 2019-2025
40 companies · $6,889 in 2025
The $6,889 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $17K · 2021: $7,879 · 2022: $13K · 2023: $6,696 · 2024: $9,788 · 2025: $6,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $9,459 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,875.00 |
| Food and Beverage | $9,458.52 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43,076.16 | 2019-2022 | |
| Abbvie INC. | $40,272.49 | 2019-2025 | Linzess, Qulipta, Ubrelvy |
| Allergan, INC. | $6,079.13 | 2019-2020 | |
| Gilead Sciences, INC. | $2,032.78 | 2019-2025 | Vemlidy, Livdelzi, Yeztugo |
| Bayer Healthcare Pharmaceuticals INC. | $1,787.39 | 2021-2025 | |
| Amgen INC. | $1,580.19 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,412.88 | 2019-2025 | Tezspire, Farxiga |
| Novo Nordisk INC | $1,149.11 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $746.42 | 2019-2024 | Xarelto |
| Pfizer INC. | $719.72 | 2019-2024 | |
| Horizon Therapeutics Plc | $683.81 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $612.87 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.67 | 2019-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $397.68 | 2020-2025 | Rexulti |
| Dexcom, INC. | $377.22 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.